Allos Therapeutics to Present at the 2007 BMO Capital Markets Focus on Healthcare Conference
30 November 2007 - 12:00AM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 29 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer, today announced that the
Company will participate in the 2007 BMO Capital Markets Focus on
Healthcare Conference in New York. The Company's presentation will
take place at 9:00 a.m. (Eastern) on December 5, 2007. There will
be a live webcast of the presentation, which will be accessible
through a link posted on the Allos website home page and investor
relations section. The webcast will be available for replay on
Allos' website through December 21, 2007. About Allos Therapeutics,
Inc. Allos Therapeutics is a biopharmaceutical company focused on
the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company's lead
product candidate, PDX (pralatrexate), is a novel antifolate
currently under evaluation in a pivotal Phase 2 (PROPEL) trial in
patients with relapsed or refractory peripheral T-cell lymphoma.
The PROPEL trial is being conducted under an agreement reached with
the U.S. Food and Drug Administration under its special protocol
assessment, or SPA process. The Company is also investigating PDX
in patients with non-small cell lung cancer and a range of lymphoma
sub-types. The Company's other product candidate is RH1, a targeted
chemotherapeutic agent currently being evaluated in a Phase 1 trial
in patients with advanced solid tumors or non-Hodgkins Lymphoma
(NHL). For additional information, please visit the Company's
website at http://www.allos.com/. Safe Harbor Statement The
anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties. Additional
information concerning these forward-looking statements and other
factors that may cause actual results to differ materially from
those anticipated in the forward-looking statements is contained in
the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2006 and in the Company's
other periodic reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the
presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek Cole, Vice
President, Investor Relations of Allos Therapeutics, Inc.,
+1-720-540-5367, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics (MM) News Articles